Challenges in anticancer drug R&D in China
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference7 articles.
1. Regulatory watch: innovative drug availability in China;Shao;Nat Rev Drug Discov,2016
2. Chinese biopharma starts feeding the global pipeline;Mullard;Nat Rev Drug Discov,2017
3. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011
4. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial;Zhang;Lancet Oncol,2012
5. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials;Fang;Lancet Oncol,2018
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Acceptance Factors and Psychological Investigation of Clinical Trials in Cancer Patients;Behavioural Neurology;2023-11-24
2. Characteristics of clinical trials of new oncology drugs approved in China;Cancer;2023-11-20
3. Growing research and development of targeted anticancer drugs in China;Journal of the National Cancer Center;2023-06
4. Characteristics and Trends in Clinical Trials of Cardiovascular Drugs in China from 2009 to 2021;American Journal of Cardiovascular Drugs;2023-03-14
5. Early phase oncology clinical trials in Malaysia: current status and future perspectives;Asia-Pacific Journal of Clinical Oncology;2022-10-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2023 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3